-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, NAlFRzF7utKLKAk2W4emSHHir7GzOJSSd2rjiKQD0M2cAXAjfAcLeA/vji1Lq/xY y8hB5VJnMimE72B73O3PsA== 0001144204-07-007999.txt : 20070214 0001144204-07-007999.hdr.sgml : 20070214 20070214151504 ACCESSION NUMBER: 0001144204-07-007999 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20061231 FILED AS OF DATE: 20070214 DATE AS OF CHANGE: 20070214 EFFECTIVENESS DATE: 20070214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BAKER BROS ADVISORS LLC CENTRAL INDEX KEY: 0001263508 IRS NUMBER: 134093645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-10519 FILM NUMBER: 07619228 BUSINESS ADDRESS: STREET 1: 667 MADISON AVENUE STREET 2: 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10021 BUSINESS PHONE: 2125212418 13F-HR 1 v065784_13fhr.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 13F FORM 13F COVER PAGE Report for the Calendar Year or Quarter Ended: December 31, 2006 Check here if Amendment [ ]; Amendment Number: _____ This Amendment (Check only one.): [ ] is a restatement. [ ] adds new holdings entries. Institutional Investment Manager Filing this Report: Name: Baker Bros. Advisors, LLC -------------------------------------------- Address: 667 Madison Avenue, 17th Floor -------------------------------------------- New York, NY 10021-8029 -------------------------------------------- Form 13F File Number: 28-10519 The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Leo Kirby -------------------------------------------- Title: Chief Financial Officer -------------------------------------------- Phone: 212-339-5633 -------------------------------------------- Signature, Place, and Date of Signing: /s/ Leo Kirby New York, N.Y. February 14, 2007 - -------------------------- --------------------------- ---------------------- [Signature] [City, State] [Date] Report Type (Check only one.): [X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) [_] 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [_] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) List of Other Managers Reporting for this Manager: None FORM 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 0 ----------- Form 13F Information Table Entry Total: 74 ----------- Form 13F Information Table Entry Value: 1,073,765 ----------- (thousands) List of Other Included Managers: None
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8 TITLE OF VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY NAME OF ISSUER CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE - ----------------- ----- ----- -------- ------- --- ---- ---------- -------- ---- ------ ---- Acadia Pharmaceuticals Inc. COM 004225108 12,194 1,387,267 SH SOLE 1,387,267 Acorda Therapeutics COM 00484M106 13,447 848,908 SH SOLE 848,908 Acusphere COM 00511R870 904 370,370 SH SOLE 370,370 Adolor Corp. COM 00724X102 1,353 179,888 SH SOLE 179,888 Alexion COM 015351109 1,471 36,415 SH SOLE 36,415 Allos Therapeutics Inc. COM 019777101 38,783 6,629,493 SH SOLE 6,629,493 Altus Pharmaceuticals Inc. COM 02216N105 4,302 228,216 SH SOLE 228,216 Amylin Pharmaceuticals Inc. COM 032346108 51,314 1,422,631 SH SOLE 1,422,631 Anesiva Inc. COM 21872P501 3,911 562,800 SH SOLE 562,800 Aradigm Corp. COM 038505301 90 100,000 SH SOLE 100,000 Arena Pharmaceuticals Inc. COM 040047102 3,942 305,329 SH SOLE 305,329 Array Biopharma Inc. COM 04269X105 3,393 262,595 SH SOLE 262,595 Atherogenics Inc. COM 047439104 496 50,036 SH SOLE 50,036 Autoimmune Inc. COM 052776101 30 26,100 SH SOLE 26,100 Auxilium COM 05334D107 699 47,562 SH SOLE 47,562 Biocryst Pharmaceuticals Inc. COM 09058V103 20,299 1,755,973 SH SOLE 1,755,973 Biomarin Pharmaceutical Inc. COM 09061G101 9,670 590,004 SH SOLE 590,004 Cerus Corp. COM 157085101 6,610 1,127,982 SH SOLE 1,127,982 Coley Pharmaceutical Group Inc. COM 19388P106 5,067 522,926 SH SOLE 522,926 Columbia Labaratories Inc. COM 197779101 4,153 814,257 SH SOLE 814,257 Cotherix Inc. COM 22163T103 4,213 312,300 SH SOLE 312,300 Critical Therapeutics Inc. COM 22674T105 406 199,084 SH SOLE 199,084 Cubist Pharmaceuticals Inc. COM 229678107 2,807 155,021 SH SOLE 155,021 Curis Inc. COM 231269101 34 26,800 SH SOLE 26,800 Cyclacel Pharmaceuticals COM 23254L108 1,876 273,386 SH SOLE 273,386 Cyclacel Pharmaceuticals Pfd. Conv. Ex 6% PFD CONV EX 23254L207 511 95,500 SH SOLE 95,500 Cytokinetics Inc. COM 23282W100 11,690 1,562,802 SH SOLE 1,562,802 Emergent Biosolutions COM 29089Q105 2,746 246,100 SH SOLE 246,100 Exelisis COM 30161Q104 413 45,900 SH SOLE 45,900 Genomic Health Inc. COM 37244C101 38,058 2,046,124 SH SOLE 2,046,124 GTX Inc. COM 40052B108 264 14,800 SH SOLE 14,800 Halozyme Therapeutics Inc. COM 40637H109 7,383 917,092 SH SOLE 917,092 Hansen Medical COM 411307101 350 30,352 SH SOLE 30,352 Icagen Inc. COM 45104P104 76 75,468 SH SOLE 75,468 Idera Pharmaceuticals Inc. COM 45168K108 12,250 2,272,725 SH SOLE 2,272,725 Incyte Corp. COM 45337C102 18,811 3,221,123 SH SOLE 3,221,123 Intermune Inc. COM 45884X103 19,580 636,752 SH SOLE 636,752 Isis Pharmaceuticals Inc. COM 464330109 210 18,859 SH SOLE 18,859 Kosan COM 50064W107 643 115,870 SH SOLE 115,870 Ligand Pharmaceuticals Inc. CL B 53220K207 420 38,357 SH SOLE 38,357 Medarex Inc. COM 583916101 12,946 875,334 SH SOLE 875,334 Medimmune Inc. COM 584699102 11,129 343,792 SH SOLE 343,792 Memory Pharma COM 58606R403 373 153,006 SH SOLE 153,006 Metabasis Therapeutics Inc. COM 59101M105 18,188 2,418,735 SH SOLE 2,418,735 Micromet COM 59509C105 2,240 746,596 SH SOLE 746,596 Myriad Genetics Inc. COM 62855J104 46,498 1,485,545 SH SOLE 1,485,545 Neopharm Inc. COM 640919106 478 286,267 SH SOLE 286,267 Neose Technologies Inc. COM 640522108 1,124 504,150 SH SOLE 504,150 Neurogen Corp. COM 64124E106 30,732 5,165,065 SH SOLE 5,165,065 Nuvelo Inc. COM 67072M301 5,890 1,472,577 SH SOLE 1,472,577 Pharmacyclics Inc. COM 716933106 6,597 1,301,218 SH SOLE 1,301,218 Pozen Inc. COM 73941U102 4,395 258,690 SH SOLE 258,690 Seattle Genetics Inc. COM 812578102 31,365 5,884,589 SH SOLE 5,884,589 Spectrum Pharmaceuticals Inc. COM 84763A108 3,461 625,910 SH SOLE 625,910 Sunesis Pharmaceuticals Inc. COM 867328502 5,095 1,127,214 SH SOLE 1,127,214 Supergen COM 868059106 226,568 44,600 SH SOLE 44,600 Tapestry Pharmaceuticals Inc. COM 876031204 4,000 2,000,000 SH SOLE 2,000,000 Targacept COM 87611R306 1,328 146,750 SH SOLE 146,750 Telik Inc. COM 87959M109 60 13,634 SH SOLE 13,634 Theravance Inc. COM 88338T104 12,692 410,869 SH SOLE 410,869 Threshold Pharma COM 885807107 11,747 3,174,959 SH SOLE 3,174,959 Torreypines Therapeutics COM 89235K105 985 133,500 SH SOLE 133,500 Trimeris Inc. COM 896263100 44,180 3,475,954 SH SOLE 3,475,954 Vertex Pharmaceuticals Inc. COM 92532F100 73,956 1,976,386 SH SOLE 1,976,386 Viropharma Inc. COM 928241108 85,373 5,831,462 SH SOLE 5,831,462 Xenoport Inc. COM 98411C100 9,399 382,861 SH SOLE 382,861 Zymogenetics Inc. COM 98985T109 3,478 223,392 SH SOLE 223,392 Alexion Pharmaceuticals Notes 1.375% 2/01/2012 CONV BONDS 015351AF6 33,406 23,300,000 PRN SOLE 23,300,000 Amylin Pharmaceuticals Notes 2.5% 4/15/11 CONV BONDS 032346AD0 11,306 9,000,000 PRN SOLE 9,000,000 Biomarin Pharmaceuticals Notes 2.5% 3/29/2013 CONV BONDS 09061GAC5 22,506 18,600,000 PRN SOLE 18,600,000 Decode Genetics Notes 3.5% 4/15/2011 CONV BONDS 243586AB0 2,216 3,000,000 PRN SOLE 3,000,000 Incyte Genomics Notes 3.5% 2/15/2011 CONV BONDS 45337CAE2 15,271 19,000,000 PRN SOLE 19,000,000 Intermune Inc Notes .25% 3/01/2011 CONV BONDS 45884XAC7 12,718 8,500,000 PRN SOLE 8,500,000 Medarex Inc Notes 2.25% 5/15/2011 CONV BONDS 583916AG6 17,196 13,500,000 PRN SOLE 13,500,000
-----END PRIVACY-ENHANCED MESSAGE-----